News & Updates
Showing Cardiology articles
Showing
Show Multimedia Only

Milvexian prevents VTE after knee arthroplasty, bleeding risk low
02 Dec 2021
byRoshini Claire Anthony
Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.
Milvexian prevents VTE after knee arthroplasty, bleeding risk low
02 Dec 2021
Clinical insights on best medical therapy for peripheral artery disease
02 Dec 2021
byAssoc Prof. Tjun Tang; Dr. Julian Wong
Patients with lower extremity peripheral artery disease (PAD) are at high risk for major adverse cardiovascular events (MACE), major adverse limb events (MALE), mortality, and future major lower extremity amputation (LEA). PAD patients with multivessel disease or relevant comorbidities such as diabetes and kidney failure are at an even higher risks for such events. [Lancet 2018;391:219-229]







